• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novartis AG Common Stock (NY:NVS)

154.13 +2.91 (+1.93%)
Streaming Delayed Price Updated: 12:35 PM EDT, Apr 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,450,814
Open 153.77
Bid (Size) 154.12 (100)
Ask (Size) 154.16 (100)
Prev. Close 151.22
Today's Range 152.71 - 154.28
52wk Range 97.72 - 170.46
Shares Outstanding N/A
Dividend Yield 2.59%
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Novartis AG-Sponsored ADR (NYSE:NVS) Presents a Compelling Case for Dividend Investors ↗
Today 4:21 EDT
Via Chartmill
News headline image
The "Liberation Day" Shockwave: US Finalizes 100% Tariffs on Branded Pharmaceutical Imports
April 06, 2026
In a move that has sent shockwaves through the global healthcare industry, the U.S. Administration officially finalized a sweeping new trade policy on April 6, 2026, imposing 100% tariffs on branded... 
Via MarketMinute
Topics Economy World Trade

Performance

YTD
+11.3%
+11.3%
1 Month
-5.3%
-5.3%
3 Month
+8.3%
+8.3%
6 Month
+17.2%
+17.2%
1 Year
+49.8%
+49.8%

More News

Read More
News headline image
Trump Issues Landmark Executive Order: 100% Tariffs on Imported Patented Drugs to Force Onshoring
April 03, 2026
Via MarketMinute
Topics Economy Government Lawsuit
Novartis AG-Sponsored ADR (NYSE:NVS): A Methodical Pick for Steady Dividend Income ↗
March 13, 2026
Via Chartmill
News headline image
Legend Biotech (LEGN) Q4 2024 Earnings Transcript ↗
April 01, 2026
Via The Motley Fool
Topics Earnings Economy World Trade
News headline image
Legend Biotech (LEGN) Q1 2025 Earnings Transcript ↗
April 01, 2026
Via The Motley Fool
News headline image
Biogen's $5.6 Billion Acquisition of Apellis: A Strategic Pivot into Rare Kidney Diseases
March 31, 2026
Via MarketMinute
News headline image
Could Investing $10,000 in VYMI Make You a Millionaire? ↗
March 30, 2026
Via The Motley Fool
Topics ETFs Stocks
News headline image
Novartis Bets $2 Billion To Deepen Allergy Drug Pipeline ↗
March 27, 2026
Via Benzinga
News headline image
International ETFs: EEM and IEFA Offer Distinct Global ETF Choices ↗
March 27, 2026
Via The Motley Fool
Topics ETFs
News headline image
Sarepta Therapeutics (SRPT) Stock Surges 34.98% on Breakthrough Clinical Data
March 26, 2026
Via MarketMinute
News headline image
The Second Act: A Deep-Dive into Corcept Therapeutics and the FDA Approval of Lifyorli
March 26, 2026
Via Finterra
Topics Economy Intellectual Property
News headline image
The $6.7 Billion Pivot: A Deep Dive into Terns Pharmaceuticals (TERN) and the Merck Acquisition
March 25, 2026
Via Finterra
Topics Initial Public Offering Intellectual Property World Trade
News headline image
Retirees: Collect a High Dividend While Diversifying Your Portfolio With This ETF ↗
March 24, 2026
Via The Motley Fool
Topics ETFs Retirement
News headline image
3 ETFs Built for the Volatile Market We're Seeing in March 2026 ↗
March 22, 2026
Via The Motley Fool
Topics ETFs Economy Stocks
News headline image
Novartis Strikes $3 Billion Deal For Next-Gen Breast Cancer Drug ↗
March 20, 2026
Via Benzinga
News headline image
The High-Stakes Gambit: How Healthcare Giants are 'Front-Loading' Megadeals to Outrun Regulatory Storms
March 18, 2026
Via MarketMinute
Topics Artificial Intelligence Intellectual Property
News headline image
Novartis Advances Dermatology Portfolio With Cosentyx FDA Approval For Pediatric Patients ↗
March 16, 2026
Via Benzinga
News headline image
VYMI: This International ETF Could Help You Earn Higher Dividends ↗
March 12, 2026
Via The Motley Fool
Topics ETFs
News headline image
3 ETFs to Avoid as Oil Shock Hits Markets ↗
March 12, 2026
Via MarketBeat
Topics ETFs
News headline image
Vertex Pharmaceuticals Surges as Breakthrough Kidney Data Sets New Gold Standard for IgA Nephropathy
March 10, 2026
Via MarketMinute
News headline image
Pfizer (PFE) 2026 Research Feature: The High-Stakes Pivot to Oncology and Obesity
March 10, 2026
Via Finterra
Topics Economy Intellectual Property Lawsuit
News headline image
Forget Amarin: This Oft-Overlooked Pharma Powerhouse Is a Better Buy Now ↗
March 03, 2026
Via The Motley Fool
Topics Intellectual Property
News headline image
As Investors Flee U.S. Equities, This Global ETF Is Outperforming ↗
March 02, 2026
Via MarketBeat
Topics ETFs
News headline image
Second HeLa Lawsuit Resolved As Novartis Reaches Confidential Settlement ↗
February 28, 2026
Via Benzinga
Topics Lawsuit

Frequently Asked Questions

Is Novartis AG Common Stock publicly traded?
Yes, Novartis AG Common Stock is publicly traded.
What exchange does Novartis AG Common Stock trade on?
Novartis AG Common Stock trades on the New York Stock Exchange
What is the ticker symbol for Novartis AG Common Stock?
The ticker symbol for Novartis AG Common Stock is NVS on the New York Stock Exchange
What is the current price of Novartis AG Common Stock?
The current price of Novartis AG Common Stock is 154.13
When was Novartis AG Common Stock last traded?
The last trade of Novartis AG Common Stock was at 04/08/26 12:35 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap